ALLOPURINOL Drug Patent Profile
✉ Email this page to a colleague
When do Allopurinol patents expire, and what generic alternatives are available?
Allopurinol is a drug marketed by Accord Hlthcare, Aiping Pharm Inc, Chartwell, Endo Operations, Harman Finochem, Hetero Labs Ltd V, Indoco, Ipca Labs Ltd, Lupin Ltd, Mutual Pharm, Mylan, Northstar Hlthcare, Puracap Pharm, Purepac Pharm, Sandoz, Sun Pharm Inds Inc, Sun Pharm Industries, Superpharm, Unichem, Watson Labs, Zydus Pharms, Gland Pharma Ltd, and Hikma. and is included in thirty NDAs.
The generic ingredient in ALLOPURINOL is allopurinol sodium. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the allopurinol sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Allopurinol
A generic version of ALLOPURINOL was approved as allopurinol sodium by HIKMA on August 26th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ALLOPURINOL?
- What are the global sales for ALLOPURINOL?
- What is Average Wholesale Price for ALLOPURINOL?
Summary for ALLOPURINOL
US Patents: | 0 |
Applicants: | 23 |
NDAs: | 30 |
Finished Product Suppliers / Packagers: | 39 |
Raw Ingredient (Bulk) Api Vendors: | 274 |
Clinical Trials: | 222 |
Patent Applications: | 4,943 |
Drug Prices: | Drug price information for ALLOPURINOL |
Drug Sales Revenues: | Drug sales revenues for ALLOPURINOL |
What excipients (inactive ingredients) are in ALLOPURINOL? | ALLOPURINOL excipients list |
DailyMed Link: | ALLOPURINOL at DailyMed |
Recent Clinical Trials for ALLOPURINOL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Urica Therapeutics Inc. | Phase 1/Phase 2 |
Eli Lilly and Company | Phase 2 |
Dana-Farber Cancer Institute | Phase 2 |
Pharmacology for ALLOPURINOL
Drug Class | Xanthine Oxidase Inhibitor |
Mechanism of Action | Xanthine Oxidase Inhibitors |
Medical Subject Heading (MeSH) Categories for ALLOPURINOL
Anatomical Therapeutic Chemical (ATC) Classes for ALLOPURINOL
US Patents and Regulatory Information for ALLOPURINOL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Watson Labs | ALLOPURINOL | allopurinol | TABLET;ORAL | 018241-002 | Nov 16, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sun Pharm Industries | ALLOPURINOL | allopurinol | TABLET;ORAL | 071450-002 | Jan 9, 1987 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Zydus Pharms | ALLOPURINOL | allopurinol | TABLET;ORAL | 210117-002 | Oct 12, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Purepac Pharm | ALLOPURINOL | allopurinol | TABLET;ORAL | 070580-001 | Apr 14, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sun Pharm Industries | ALLOPURINOL | allopurinol | TABLET;ORAL | 071450-001 | Jan 9, 1987 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sandoz | ALLOPURINOL | allopurinol | TABLET;ORAL | 070269-001 | Dec 31, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Accord Hlthcare | ALLOPURINOL | allopurinol | TABLET;ORAL | 203154-001 | May 6, 2013 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |